Back to Journals » Medical Devices: Evidence and Research » Volume 11

Spotlight on the SAPIEN 3 transcatheter heart valve

Authors Rheude T, Blumenstein J, Möllmann H, Husser O

Received 22 May 2018

Accepted for publication 24 July 2018

Published 1 October 2018 Volume 2018:11 Pages 353—360


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Tobias Rheude,1 Johannes Blumenstein,2 Helge Möllmann,2 Oliver Husser2

1Department of Cardiovascular Diseases, German Heart Centre, Technical University Munich, Munich, Germany; 2Department of Cardiology, St.-Johannes-Hospital, Dortmund, Germany

Abstract: Transcatheter aortic valve implantation (TAVI) is increasingly performed in patients with severe aortic stenosis. The efficacy and safety have been demonstrated in large randomized trials in patients with high- or intermediate operative risk. With latest-generation transcatheter heart valve (THV) systems, growing operator experience and improved patient selection, clinical outcome has significantly improved with a decline of TAVI-related complications. In this review, the Edwards SAPIEN 3 THV is discussed in terms of technology, procedural advances and complication trends and future developments.

Keywords: aortic valve stenosis, transcatheter aortic valve implantation, TAVI, transcatheter heart valves, Edwards SAPIEN 3

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]